At ESC Congress 2019 Scott D. Solomon (Brigham and Women’s Hospital, Harvard Medical School, Boston) presented the results of PARAGON-HF trial about the use of sacubitril/valsartan in HFpEF patients. The results didn’t get statistic relevance for the primary endpoint (a composite of first and recurrent HF hospitalisations and cv death), but data suggest there may be benefit for some patients group.
- PARAGON-HF: dati interlocutori per sacubitril/valsartan
Presentati a ESC 2019 i risultati relativi ai pazienti con frazione di eiezione preservata.
- The COMMANDER-HF trial
John G.F. Cleland National Heart and Lung Institute, Imperial College London